Brazil Makes Drug Prices Transparent To Strengthen Hand In Pricing Talks
Executive Summary
Brazil wants to drive competition and lower drug prices by obliging health authorities to publish the prices paid for all drugs bought by the national health system. A voluntary system has already helped save $1bn and cut the price of Gilead’s Sovaldi by around 30%.
You may also be interested in...
Brazil Prepares To Make Its Own Sovaldi As Regulator Opposes Patent Application
Brazil could soon be manufacturing its own generic version of Gilead’s Sovaldi if opposition to the company’s patent application is upheld by the patent office.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.